Neovascular AMD: Bevacizumab Injection Increases Angiogenic Biomarkers

Neovascular age-related macular degeneration (nAMD) is induced by the development of new abnormal ‘leaky’ blood vessels in the choroid and retina, when the balance of pro- and anti-angiogenic factors is upset. Vascular endothelial growth factor (VEGF) is considered a critical modulator of angiogenesis and is related to induction of endothelial cell migration and proliferation after


Misión de Alcance a Sacaba, Cochabamba, Bolivia

~ Dr. Anthony Maida, Coordinador, proyecto #BOLDR, Cochabamba, Bolivia   Para este alcance, el 12 de mayo de 2018, tuvimos la oportunidad de interactuar con la comunidad de Sacaba, una ciudad ubicada a 13 kilómetros al este de la ciudad de Cochabamba. Tiene una población de 172,466 según el último censo en 2017.   Hicimos


Start of the #BOLDR Project in Cochabamba, Bolivia

This report has been written by Dr. Georgia Kamboj, Research Manager, Retina Global.   The World Diabetes Foundation has approved funding to support the “Bolivian Diabetic Retinopathy Project” (#BOLDR). The preliminary (or Phase I) part of this project will be conducted over 3 years, in the city of Cochabamba and its surrounding regions, with an


(c) GenSight Biologics

GenSight receives approval for PIONEER trial to evaluate GS030, a combination Gene Therapy & Device treatment for patients with RP. May test AMD later.

GenSight Biologics, a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced UK Medicines and Healthcare Regulatory Agency (MHRA) acceptance of the Company’s Clinical Trial Application (CTA) to initiate the PIONEER Phase I/II study of GS030 in patients with Retinitis Pigmentosa (RP).

President Trump looking at the solar eclipse

Solar Retinopathy: What may happen when you look at the solar eclipse without eye protection?

By reading this article, your agree that you have read the disclaimer at the end of this article, and agree with its contents in their entirety. Many of the millions of people who watched yesterday’s solar eclipse will have used proper eye protection before turning their gaze towards the spectacle in the sky. Others may have used


Macular degeneration

Ophthotech Fovista AMD Phase 3 trials results come up short

Ophthotech Corporation has announced that the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its Phase 3 clinical trial investigating the superiority of Fovista® (pegpleranib) anti-PDGF therapy in combination with Eylea® (aflibercept) or Avastin® (bevacizumab) anti-VEGF therapy compared to Eylea or Avastin monotherapy for the treatment of